Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 10/2020

01-10-2020 | Obesity | Original Contributions

Acute and Chronic Impact of Biliopancreatic Diversion with Duodenal Switch Surgery on Plasma Lipoprotein(a) Levels in Patients with Severe Obesity

Authors: Audrey-Anne Després, Marie-Eve Piché, Audrey Auclair, Laurent Biertho, Simon Marceau, Frédéric-Simon Hould, Simon Biron, Stéfane Lebel, Odette Lescelleur, François Julien, Julie Martin, André Tchernof, Patrick Mathieu, Paul Poirier, Benoit J. Arsenault

Published in: Obesity Surgery | Issue 10/2020

Login to get access

Abstract

Background

Elevated lipoprotein(a) (Lp(a)) level is an independent risk factor for cardiovascular diseases. Lifestyle intervention studies targeting weight loss revealed little to no significant changes in Lp(a) levels. The impact of interventions that induce substantial weight loss, such as bariatric surgery, on Lp(a) levels is currently unclear.

Objective

To determine the acute and long-term impact of bariatric surgery on Lp(a) levels in patients with severe obesity.

Methods

Sixty-nine patients with severe obesity underwent biliopancreatic diversion with duodenal switch (BPD-DS) surgery. The lipid profile was evaluated and Lp(a) levels were measured before surgery and at 6 and 12 months after BPD-DS surgery.

Results

Median Lp(a) levels at baseline were 11.1 (4.1–41.6) nmol/L. Six months and 12 months after the BDP-DS surgery, we observed an improvement of lipid profile. At 6 months, we observed a 13% decrease in Lp(a) levels (9.7 (2.9–25.6) nmol/L, p < 0.0001) but this decrease was not sustained at 12 months (11.1 (3.9–32.8) nmol/L, p = 0.8). When the patients were separated into tertiles according to Lp(a) levels at baseline, we observed that the Lp(a) reduction at 12 months after BPD-DS surgery remained significant but modest in patients of the top Lp(a) tertile.

Conclusion

Our results suggest that BPD-DS surgery modestly reduces Lp(a) levels in the short term (6 months) in patients with severe obesity but this improvement is sustained over time only in patients with higher Lp(a) levels.
Literature
1.
Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518–28.PubMedCrossRef
2.
Emdin CA, Khera AV, Natarajan P, et al. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. J Am Coll Cardiol. 2016;68(25):2761–72.PubMedPubMedCentralCrossRef
3.
Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90(1):52–60.PubMedPubMedCentralCrossRef
4.
5.
Sonnichsen AC, Richter WO, Schwandt P. Reduction of lipoprotein (a) by weight loss. Int J Obes. 1990;14(6):487–94.PubMed
6.
Kiortsis DN, Tzotzas T, Giral P, et al. Changes in lipoprotein(a) levels and hormonal correlations during a weight reduction program. Nutr Metab Cardiovasc Dis. 2001;11(3):153–7.PubMed
7.
Berk KA, Yahya R, Verhoeven AJM, et al. Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 diabetes. Diabetologia. 2017;60(6):989–97.PubMedPubMedCentralCrossRef
8.
Piche ME, Auclair A, Harvey J, et al. How to choose and use bariatric surgery in 2015. Can J Cardiol. 2015;31(2):153–66.PubMedCrossRef
9.
Boyer M, Lévesque V, Poirier P, et al. Impact of a 1-year lifestyle modification program on plasma lipoprotein and PCSK9 concentrations in patients with coronary artery disease. J Clin Lipidol. 2016;10(6):1353–61.PubMedCrossRef
10.
Boman L, Ericson M. Lipoprotein a levels after intestinal bypass operation for morbid obesity. Obes Surg. 1997;7(2):125–7.PubMedCrossRef
11.
Williams DB, Hagedorn JC, Lawson EH, et al. Gastric bypass reduces biochemical cardiac risk factors. Surg Obes Relat Dis. 2007;3(1):8–13.PubMedCrossRef
12.
Lin BX, Weiss MC, Parikh M, et al. Changes in lipoprotein(a) following bariatric surgery. Am Heart J. 2018;197:175–6.PubMedCrossRef
13.
Piché M-È, Martin J, Cianflone K, et al. Changes in predicted cardiovascular disease risk after biliopancreatic diversion surgery in severely obese patients. Metabolism. 2014;63(1):79–86.PubMedCrossRef
14.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.PubMedCrossRef
15.
To VT, Huttl TP, Lang R, et al. Changes in body weight, glucose homeostasis, lipid profiles, and metabolic syndrome after restrictive bariatric surgery. Exp Clin Endocrinol Diabetes. 2012;120(9):547–52.PubMedCrossRef
16.
Woodard GA, Peraza J, Bravo S, et al. One year improvements in cardiovascular risk factors: a comparative trial of laparoscopic Roux-en-Y gastric bypass vs. adjustable gastric banding. Obes Surg. 2010;20(5):578–82.PubMedCrossRef
17.
Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med. 2013;273(1):6–30.PubMedCrossRef
18.
Santonocito C, De Loecker I, Donadello K, et al. C-reactive protein kinetics after major surgery. Anesth Analg. 2014;119(3):624–9.PubMedCrossRef
19.
Langsted A, Varbo A, Kamstrup PR, et al. Elevated lipoprotein(a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: a study of 100,578 individuals from the general population. J Clin Endocrinol Metab. 2015;100(7):2690–9.PubMedCrossRef
20.
Missala I, Kassner U, Steinhagen-Thiessen E. A systematic literature review of the association of lipoprotein(a) and autoimmune diseases and atherosclerosis. Int J Rheumatol. 2012;2012:480784.PubMedPubMedCentral
21.
Langsted A, Kamstrup PR, Nordestgaard BG. Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis. 2014;234(1):95–101.PubMedCrossRef
22.
Muller N, Schulte DM, Turk K, et al. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res. 2015;56(5):1034–42.PubMedPubMedCentralCrossRef
23.
Illan-Gomez F, Gonzalvez-Ortega M, Orea-Soler I, et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg. 2012;22(6):950–5.PubMedCrossRef
24.
Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010;5(12):e14328.PubMedPubMedCentralCrossRef
25.
Shin MJ, Blanche PJ, Rawlings RS, et al. Increased plasma concentrations of lipoprotein(a) during a low-fat, high-carbohydrate diet are associated with increased plasma concentrations of apolipoprotein C-III bound to apolipoprotein B-containing lipoproteins. Am J Clin Nutr. 2007;85(6):1527–32.PubMedCrossRef
26.
Silaste ML, Rantala M, Alfthan G, et al. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol. 2004;24(3):498–503.PubMedCrossRef
27.
Faghihnia N, Tsimikas S, Miller ER, et al. Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J Lipid Res. 2010;51(11):3324–30.PubMedPubMedCentralCrossRef
28.
Ginsberg HN, Kris-Etherton P, Dennis B, et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol. 1998;18(3):441–9.PubMedCrossRef
29.
Haring B, von Ballmoos MC, Appel LJ, et al. Healthy dietary interventions and lipoprotein (a) plasma levels: results from the Omni Heart Trial. PLoS One. 2014;9(12):e114859.PubMedPubMedCentralCrossRef
30.
Jahansouz C, Xu H, Hertzel AV, et al. Bile acids increase independently from hypocaloric restriction after bariatric surgery. Ann Surg. 2016;264(6):1022–8.PubMedCrossRef
31.
32.
Calmarza P, Bajador E, Lapresta C, et al. Effect of biliary obstruction on lipoprotein(a) concentration. Clin Investig Arterioscler. 2014;26(5):218–23.PubMed
33.
Reyes-Soffer G, Pavlyha M, Ngai C, et al. Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation. 2017;135(4):352–62.PubMedPubMedCentralCrossRef
34.
Arsenault BJ, Petrides F, Tabet F, et al. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. J Clin Lipidol. 2018;12(1):130–6.PubMedCrossRef
Metadata
Title
Acute and Chronic Impact of Biliopancreatic Diversion with Duodenal Switch Surgery on Plasma Lipoprotein(a) Levels in Patients with Severe Obesity
Authors
Audrey-Anne Després
Marie-Eve Piché
Audrey Auclair
Laurent Biertho
Simon Marceau
Frédéric-Simon Hould
Simon Biron
Stéfane Lebel
Odette Lescelleur
François Julien
Julie Martin
André Tchernof
Patrick Mathieu
Paul Poirier
Benoit J. Arsenault
Publication date
01-10-2020
Publisher
Springer US
Published in
Obesity Surgery / Issue 10/2020
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-020-04450-2

Other articles of this Issue 10/2020

Obesity Surgery 10/2020 Go to the issue

Original Contributions

Different Malabsorptive Obesity Surgery Interventions Result in Distinct Postprandial Amino Acid Metabolomic Signatures

Original Contributions

Preoperative Chemerin Level Is Predictive of Inflammatory Status 1 Year After Bariatric Surgery

Original Contributions

Tolerance to Specific Foods After Laparoscopic Sleeve Gastrectomy

Correction

Correction to: Evaluation of Liver Function Tests and Risk Score Assessment to Screen Patients for Significant Liver Disease Prior to Bariatric and Metabolic Surgery

Brief Communication

Jejuno-Jejunal Intussusception after Roux-en-Y Gastric Bypass

Original Contributions

Psychopharmacological Medication Has No Influence on Vitamin Status After Bariatric Surgery in Long-term Follow-up